Non-invasive measurement of analytes

• US 8,509,867 B2
• Filed: 02/07/2006
• Issued: 08/13/2013
• Est. Priority Date: 11/12/2002
• Status: Active Grant

• Current Assignee: Cercacor Laboratories
• Original Assignee: Cercacor Laboratories
• Inventors: Workman, Jerome J., Lambert, Christopher R., Coleman, Robert L.
• Primary Examiner(s): Ford, Allison
• Assistant Examiner(s): FERNANDEZ, SUSAN EMILY
• Application Number:
  US11/349,731
• Publication Number:
  US 20070020181A1
• Time in Patent Office: 2,744 Days
• Field of Search: None
• US Class Current: 600/316
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14539 for measuring pH
• CPC Class Codes: A61B 5/1455 using optical sensors, e.g. spectral photometrical oximeters
• CPC Class Codes: A61B 5/413 Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant
• CPC Class Codes: A61B 5/415 the glands, e.g. tonsils, adenoids or thymus
• CPC Class Codes: A61B 5/418 lymph vessels, ducts or nodes
• CPC Class Codes: A61K 49/0041 Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal in vivo G01N
• CPC Class Codes: A61K 49/0052 Small organic molecules oligomers, polymers, dendrimers A61K49/0054
• CPC Class Codes: C12Q 1/54 involving glucose or galactose
• CPC Class Codes: Y10T 436/144444 Glucose

Abstract

This invention provides devices, compositions and methods for determining the concentration of one or more metabolites or analytes in a biological sample, including cells, tissues, organs, organisms, and biological fluids. In particular, this invention provides materials, apparatuses, and methods for several non-invasive techniques for the determination of in vivo blood glucose concentration levels based upon the in vivo measurement of one or more biologically active molecules found in skin.

Claims

1. An in vivo method for monitoring the concentration of blood glucose, the method comprising:

applying at least one small molecule metabolic reporter (SMMR) to at least one surface of skin for a predetermined period of time;

causing penetration of the at least one SMMR to a location having a depth corresponding to the stratum germinativum;

controlling a temperature at said location, wherein said controller increases blood flow to the dermal layer below said location;

monitoring a change in the stratum germinativum intracellular concentration of glucose in a metabolic pathway by detecting changes in the at least one SMMR at one or more time points using an optical reader; and

correlating the change in the stratum germinativum intracellular glucose concentration with in vivo blood glucose levels.

2. The method of claim 1, wherein the at least one SMMR comprises a mitochondrial stain sensitive to membrane potential or chemical gradient.

3. The method of claim 2, wherein the mitochondrial stain is a polycyclic aromatic hydrocarbon dye selected from the group consisting of:

rhodamine 123;

di-4-ANEPPS;

di-8-ANEPPS;

DiBAC₄(3);

RH421;

tetramethylrhodamine ethyl ester, perchlorate;

tetramethylrhodamine methyl ester, perchlorate;

2-(4-(dimethylamino)styryl)-N-ethylpyridinium iodide;

3,3′

-dihexyloxacarbocyanine;

5,5′

,6,6′

-tetrachloro-1,1′

,3,3′

-tetraethyl-benzimidazolylcarbocyanine chloride;

5,5′

,6,6′

-tetrachloro-1,1′

,3,3′

-tetraethyl-benzimidazolylcarbocyanine iodide;

nonylacridine orange;

dihydrorhodamine 123;

dihydrorhodamine 123, dihydrochloride salt;

xanthene;

2′

,7′

-bis-(2-carboxyethyl)-5-(and -6)-carboxyfluorescein;

benzenedicarboxylic acid, 2(or

     4)-[10-(dimethylamino)-3-oxo-3-H-benzo[c]xanthene-7-yl]; and

iodine dissolved in potassium iodide.

4. The method of claim 1, wherein the at least one SMMR comprises a dye or stain that transfers energy from a molecule generated as a result of an oxidative metabolic pathway and that has a stoichiometric or substantially stoichiometric relationship with glucose concentration.

5. The method of claim 1, wherein the at least one SMMR comprises a dye selected from the group consisting of:

coumarin;

anthraquinones;

cyanine dyes;

azo dyes;

xanthene dyes;

arylmethine dyes; and

ruthenium bipyridyl complexes.

6. The method of claim 1, wherein the at least one SMMR comprises a protein labeled fluorophore.

7. The method of claim 6, wherein the protein labeled fluorophore is Glucose Oxidase-Labeled Fluorophore (GO-LF) or Glucose Oxidase-Intercalated Fluorophore (GO-IF).

8. The method of claim 1, wherein the at least one SMMR comprises a protein comprising a photooxidizable cofactor.

9. The method of claim 8, wherein the protein comprising a photooxidizable cofactor is Glucose Oxidase (GOx) with a flavin adenine dinucleotide (FAD) in the triplet state (GOx-³FAD*).

10. The method of claim 1, wherein monitoring the change in the stratum germinativum intracellular glucose concentration comprises detecting radiation at least one wavelength above 350 nm.

11. The method of claim 1, wherein the at least one SMMR is formulated as a cream, emulsion, ointment, oil, disposable gel film patch, reservoir device or paint.

12. The method of claim 1, wherein the at least one SMMR penetrates within the skin using at least one technique selected from the group consisting of:

electroporation, solvent transport, tattooing, injecting, microneedle delivery, and passive transport.

13. The method of claim 1, wherein the monitoring comprises quantification of the change in fluorescence or absorption using fluorescence or absorption spectroscopy.

14. The method of claim 1, wherein the at least one SMMR penetrates within the skin using microneedle delivery.

15. An in vivo method for measuring blood glucose levels, said in vivo method comprising controlling a temperature at a population of stratum germinativum cells to increase blood flow to a dermal layer below said stratum germinativum cells, and monitoring intracellular glucose concentration in the population of stratum germinativum cells, wherein the monitoring comprises measuring the fluorescence spectrum emitted by at least one small molecule metabolic reporter (SMMR), wherein at least one fluorescence spectrum emitted by the at least one SMMR is stoichiometrically related to the glucose intracellular concentration in the population of stratum germinativum cells, whereby analyzing the relatedness provides the in vivo blood glucose level.

16. The method of claim 15, wherein the population of stratum germinativum cells has a predominantly glycolytic metabolism or can be induced to have a glycolytic metabolism.

17. The method of claim 16, wherein the population of stratum germinativum cells is located in the epidermis, wherein the epidermis comprises a dynamic, metabolically homogeneous, and homeostatic population of cells.

18. The method of claim 16, wherein the population of stratum germinativum cells having a glycolytic metabolism comprise live keratinocytes.

19. The method of claim 15, wherein the intracellular glucose concentration is monitored in the population of stratum germinativum cells via measurement of one or more specific metabolite or analyte of the glycolytic pathway that has a stoichiometric or substantially stoichiometric relationship with glucose concentration.

20. The method of claim 15, wherein the monitoring of intracellular glucose concentration in the population of stratum germinativum cells, comprises measuring a physico-chemical parameter that is related to the glycolytic pathway, wherein said physic-chemical parameter comprises a stoichiometric or substantially stoichiometric relationship with glucose concentration.

21. The method of claim 15, wherein the population of stratum germinativum cells comprises a predominantly oxidative metabolism or can be induced to comprise a metabolism predominantly based on oxidative phosphorylation.

22. The method of claim 21, wherein the monitoring of intracellular glucose concentration in the population of stratum germinativum cells, comprises measuring a metabolite or analyte that is generated as a result of an oxidative metabolic pathway, wherein said metabolite or analyte comprises a stoichiometric or substantially stoichiometric relationship with glucose concentration.

23. The method of claim 21, wherein the monitoring of intracellular glucose concentration in the population of stratum germinativum cells, comprises measuring a physico-chemical parameter that is generated as a result of an oxidative metabolic pathway and that comprises a stoichiometric or substantially stoichiometric relationship with glucose concentration.

24. A noninvasive method for monitoring in vivo blood glucose levels, the method comprising:

applying at least one small molecule metabolic reporter (SMMR) to at least one surface of skin for a predetermined period of time;

causing penetration of the at least one SMMR to a location corresponding to the stratum germinativum;

contacting the at least one SMMR with one or more metabolites or analytes indicative of stratum germinativum intracellular glucose concentration;

controlling a temperature at said location, wherein said controlling increases blood flow to the dermal layer below said location;

monitoring a change in the stratum germinativum intracellular glucose concentration by detecting changes in the at least one SMMR using an optical reader, and

correlating the change in the stratum germinativum intracellular glucose concentration with in vivo blood glucose levels.

25. The method of claim 24, wherein the at least one small molecule metabolic reporter is selected from the group consisting of a fluorophore, a protein labeled fluorophore, a protein comprising a photooxidizable cofactor, a protein comprising an intercalated fluorophore, a mitochondrial vital stain or dye, a dye exhibiting one or more of a redox potential, a membrane localizing dye, a dye comprising energy transfer properties, a pH indicating dye, a coumarin dye, an anthraquinone dye, a cyanine dye, an azo dye, a xanthene dye, an arylmethine dye, and a ruthenium bipyridyl complex dye.

26. The method of claim 25, wherein the protein labeled fluorophore is Glucose Oxidase-Labeled Fluorophore (GO-LF) and the one or more metabolites is glucose.

27. The method of claim 25, wherein the protein comprising a photooxidizable cofactor is Glucose Oxidase (GOx) with a flavin adenine dinucleotide (FAD) in the triplet state (GOx ³FAD*).

28. The method of claim 25, wherein the mitochondrial vital stain or dye is a polycyclic aromatic hydrocarbon dye selected from the group consisting of:

Rhodamine 123;

Di-4-ANEPPS;

Di-8-ANEPPS;

DiBAC₄(3);

RH421;

Tetramethylrhodamine ethyl ester, perchlorate;

Tetramethylrhodamine methyl ester, perchlorate;

2-(4-(dimethylamino)styryl)-N-ethylpyridinium iodide;

3,3′

-Dihexyloxacarbocyanine;

5,5′

,6,6′

-tetrachloro-1,1′

,3,3′

-tetraethyl-benzimidazolylcarbocyanine chloride;

5,5′

,6,6′

-tetrachloro-1,1′

,3,3′

-tetraethyl-benzimidazolylcarbocyanine iodide;

Nonylacridine Orange;

Dihydrorhodamine 123;

Dihydrorhodamine 123, dihydrochloride salt;

xanthene;

2′

,7′

-bis-(2-carboxyethyl)-5-(and -6)-carboxyfluorescein;

benzenedicarboxylic acid, 2(or

     4)-[10-(dimethylamino)-3-oxo-3-H-benzo[c]xanthene-7-yl]; and

iodine dissolved in potassium iodide.

29. The method of claim 25, where monitoring the change in stratum germinativum intracellular glucose concentration comprises measuring at least one spectral emission at a wavelength above 450 nm.

30. The method of claim 24, wherein the one or more metabolites or analytes are selected from the group consisting of glucose, lactate, H⁺, Ca²⁺, Mg²⁺, Na⁺, K⁺, ATP, ADP, P_i, glycogen, pyruvate, NAD(P)+, NAD(P)H, FAD, FADH₂, and O₂.

31. A method for determining in vivo blood glucose concentration, comprising the steps of:

performing an instrument response measurement on a calibration target and recording the response data;

applying a mixture comprising at least one SMMR to the skin in a first controlled area such that the at least one SMMR resides in the stratum germinativum layer of the skin;

applying a second mixture comprising at least one SMMR to the skin in a second controlled area;

perturbing the second controlled area such that one or more extreme changes at the second controlled area are achieved;

performing a calibration measurement on the perturbed area and recording the calibration data;

performing a background measurement on an area of skin that has no SMMR and recording this background data;

controlling a temperature at the first controlled area, wherein said controlling increases blood flow to a dermal layer below the first controlled area;

illuminating the first controlled area with light and performing a first measurement on the first controlled area;

detecting at least one wavelength spectrum of light reflected back from the first controlled area;

performing at least a second measurement on the first controlled area at wavelengths suitable for each SMMR present;

calculating at least one parameter from the response data to normalize the background data, calibration data and measurement data for the response using a spectrometer;

calculating at least one parameter from the background data to correct the calibration data and measurement data for emission, absorption and scattering properties of the tissue; and

calculating at least one stratum germinativum intracellular glucose parameter from the calibration data to relate the measurement data to the blood glucose concentration;

thereby determining in vivo blood glucose concentration.

32. The method of claim 31, wherein the one or more extreme changes is a change in concentration of a metabolite or analyte between a zero or near zero concentration and a saturation level or near saturation level concentration.

33. The method of claim 31, wherein the mixture comprising at least one SMMR penetrates within the stratum germinativum layer of skin using microneedle delivery.